Universe Pharmaceuticals (Universe Pharmaceuticals) EBITDA Margin % : -27.27% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Universe Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Universe Pharmaceuticals's EBITDA for the six months ended in Sep. 2023 was $-3.78 Mil. Universe Pharmaceuticals's Revenue for the six months ended in Sep. 2023 was $13.84 Mil. Therefore, Universe Pharmaceuticals's EBITDA margin for the quarter that ended in Sep. 2023 was -27.27%.

Universe Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Universe Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universe Pharmaceuticals EBITDA Margin % Chart

Universe Pharmaceuticals Annual Data

Trend

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBITDA Margin %

Get a 7-Day Free Trial

30.70

34.63

29.65

-18.16

-9.85

Universe Pharmaceuticals Semi-Annual Data
	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial						18.48	15.25	-68.87	3.20	-27.27

Competitive Comparison of Universe Pharmaceuticals's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universe Pharmaceuticals's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Universe Pharmaceuticals's EBITDA Margin % falls into.

Universe Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Universe Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-3.184	/	32.309
	=	-9.85 %

Universe Pharmaceuticals's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-3.775	/	13.842
	=	-27.27 %

Universe Pharmaceuticals (NAS:UPC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Universe Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Universe Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Universe Pharmaceuticals (Universe Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Universe Pharmaceuticals Inc (NAS:UPC) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

265 Jingjiu Avenue, Economic & Technological Development Zone, Jinggangshan, Jiangxi, Ji’an, CHN

Website

http://www.universe-pharmacy.com

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.